gsk201603016k7.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending March 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
Notification of Transactions of Directors and Persons Discharging Managerial Responsibility
GlaxoSmithKline Deferred Annual Bonus Plan
Withholding of shares to meet tax liabilities
The table below sets out changes in the interests of an Executive Director and Person Discharging Managerial Responsibility (PDMR) in the American Depositary Shares (ADS) of GlaxoSmithKline plc arising from the withholding of ADSs at a fair market value of $39.14 per ADS (the closing price on 26 February 2016 which was the business day prior to vesting) to meet tax liabilities following the vesting of the pre-tax awards granted in 2013 under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP). The awards vested on the third anniversary of the award date which was 28 February 2016.
| |
Number of ADSs withheld to meet tax liabilities following the vesting of a DABP award
|
|
Dr M Slaoui*
|
11,083
|
|
Mr D Troy
|
5,108
|
* Denotes an Executive Director
The Company, the Executive Director and PDMR were advised of these transactions on 29 February 2016.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
1 March 2016
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: 01 March, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc